Department of Pharmacy, Shanghai Pudong New Area Gongli Hospital, The Second Military Medical University, 219 Miaopu Road, Shanghai 200135, PR China.
Department of Pharmacy, Shanghai Chest Hospital, 241 West Huaihai Road, Shanghai 200030, PR China.
Eur J Pharm Sci. 2021 Jul 1;162:105814. doi: 10.1016/j.ejps.2021.105814. Epub 2021 Mar 19.
Biapenem is a carbapenem antibiotic. It is excreted predominantly through the kidney as unchanged forms. However, the molecular mechanism of renal excretion of biapenem and potential drug-drug interactions (DDIs) were still unknown. In the present study, the role of organic anion transporters (OAT) 1/3 and organic cation transporters (OCT) 2 in the renal excretion of biapenem, and the potential DDIs between biapenem and six clinical commonly prescribed antibiotics and antiviral drugs that acted as substrates or inhibitors of OAT3 were evaluated in vitro. Further, the effect of probenecid on the pharmacokinetics of biapenem was explored in the rats. We observed that biapenem could not inhibit the transport activities of OAT1 or OCT2, while mildly inhibited OAT3 (IC >500 μM). Among the tested antibiotics and antiviral drugs, the relatively high DDI index values (maximal unbound plasma concentration over IC, I/IC) were found for piperacillin, linezolid and benzylpenicillin, which were 2.84, 1.7 and 0.62, respectively. Although probenecid had the highest DDI index (27.1) in vitro, no significant impact of it on the pharmacokinetics of biapenem was observed in the rats. Our results indicated that biapenem was primarily eliminated by the glomerular filtration, while OAT3-mediated renal tubular secretion was a minor route. Biapenem is not a clinically relevant substrate or inhibitor because of its low affinity to OAT3. According to current results, it would be safe to use biapenem with other antibiotics and antiviral drugs that acted as substrates or inhibitors of OAT3.
比阿培南是一种碳青霉烯类抗生素。它主要以原形经肾脏排泄。然而,比阿培南经肾脏排泄的分子机制和潜在的药物相互作用(DDI)仍不清楚。在本研究中,我们评估了有机阴离子转运体(OAT)1/3 和有机阳离子转运体(OCT)2 在比阿培南肾排泄中的作用,以及比阿培南与 6 种临床常用的作为 OAT3 底物或抑制剂的抗生素和抗病毒药物之间的潜在 DDI。此外,我们还在大鼠中研究了丙磺舒对比阿培南药代动力学的影响。我们观察到比阿培南不能抑制 OAT1 或 OCT2 的转运活性,而对 OAT3 的抑制作用较弱(IC >500 μM)。在测试的抗生素和抗病毒药物中,哌拉西林、利奈唑胺和苄青霉素的相对较高的 DDI 指数值(最大未结合血浆浓度与 IC 的比值,I/IC),分别为 2.84、1.7 和 0.62。虽然丙磺舒在体外的 DDI 指数最高(27.1),但在大鼠中,它对比阿培南的药代动力学没有显著影响。我们的结果表明,比阿培南主要通过肾小球滤过清除,而 OAT3 介导的肾小管分泌是次要途径。由于比阿培南与 OAT3 的亲和力较低,因此不是一种具有临床相关性的底物或抑制剂。根据目前的结果,比阿培南与其他作为 OAT3 底物或抑制剂的抗生素和抗病毒药物联合使用是安全的。